103 related articles for article (PubMed ID: 1998996)
1. High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology study.
Beelen DW; Schilcher RB; Ehrlich R; Quabeck K; Schmidt U; Szy D; Grosse-Wilde H; Becher R; Schaefer UW
Cancer Chemother Pharmacol; 1991; 27(5):361-6. PubMed ID: 1998996
[TBL] [Abstract][Full Text] [Related]
2. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Spitzer TR; Peters C; Ortlieb M; Tefft MC; Torrisi J; Cahill R; Gadner H; Urban C; Deeg HJ
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):39-44. PubMed ID: 8175444
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy and bone marrow transplantation.
Thomas ED
Semin Oncol; 1985 Dec; 12(4 Suppl 6):15-20. PubMed ID: 3909418
[TBL] [Abstract][Full Text] [Related]
4. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
[TBL] [Abstract][Full Text] [Related]
5. alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.
Hilgard P; Peukert M; Pohl J
Cancer Treat Rev; 1984 Jun; 11(2):115-20. PubMed ID: 6498858
[TBL] [Abstract][Full Text] [Related]
6. The development of busulfan/cyclophosphamide preparative regimens.
Santos GW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
[TBL] [Abstract][Full Text] [Related]
7. Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats.
Sender V; Hofmeister-Mielke N; Sievert K; Teifke JP; Vogel H; Baumgart J; Pichlmeier U; Freund M; Casper J; Wolff D
Immunopharmacol Immunotoxicol; 2009; 31(4):595-600. PubMed ID: 19874228
[TBL] [Abstract][Full Text] [Related]
8. A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
Cunningham D; Soukop M; Stuart JF; Setanoians A; Gilchrist NL; Forrest GJ; Kaye SB
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1325-9. PubMed ID: 3830214
[TBL] [Abstract][Full Text] [Related]
9. Development of a model of melphalan-induced gastrointestinal toxicity in mice.
Castellino S; Elion GB; Griffith OW; Dewhirst M; Kurtzberg J; Cattley RC; Scott P; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1993; 31(5):376-80. PubMed ID: 8431971
[TBL] [Abstract][Full Text] [Related]
10. Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.
Bruntsch U; Dodion P; Ten Bokkel Huinink WW; Hansen HH; Pinedo HM; Hansen M; Renard J; Van Glabbeke M
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):697-9. PubMed ID: 3743605
[TBL] [Abstract][Full Text] [Related]
11. Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model.
Down JD; Berman AJ; Warhol M; Van Dijken PJ; Ferrara JL; Yeap B; Hellman S; Mauch PM
Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):109-16. PubMed ID: 2663795
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation.
Blazar BR; Ramsay NK; Kersey JH; Krivit W; Arthur DC; Filipovich AH
Transplantation; 1985 Jun; 39(6):597-603. PubMed ID: 3890287
[TBL] [Abstract][Full Text] [Related]
13. Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan.
Mauch P; Down JD; Warhol M; Hellman S
Transplantation; 1988 Aug; 46(2):205-10. PubMed ID: 3043777
[TBL] [Abstract][Full Text] [Related]
14. High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.
Blume KG; Forman SJ
Semin Oncol; 1992 Dec; 19(6 Suppl 13):63-6. PubMed ID: 1492228
[TBL] [Abstract][Full Text] [Related]
15. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Petersen FB; Buckner CD; Appelbaum FR; Clift RA; Sanders JE; Bensinger WI; Storb R; Witherspoon RP; Sullivan KM; Bearman SI
Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
[TBL] [Abstract][Full Text] [Related]
16. Influence of various conditioning regimens on the outcome of bone marrow transplantation for leukemia.
Devergie A; Socie G; Esperou-Bourdeau H; Ribaud P; Traineau R; Gluckman E
Nouv Rev Fr Hematol (1978); 1991; 33(6):437-9. PubMed ID: 1818295
[TBL] [Abstract][Full Text] [Related]
17. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
[TBL] [Abstract][Full Text] [Related]
18. Risk factors in interstitial pneumonitis following allogenic bone marrow transplantation.
Pino y Torres JL; Bross DS; Lam WC; Wharam MD; Santos GW; Order SE
Int J Radiat Oncol Biol Phys; 1982 Aug; 8(8):1301-7. PubMed ID: 6754666
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of agents used in bone marrow transplant conditioning regimens.
Wiebe VJ; Smith BR; DeGregorio MW; Rappeport JM
Crit Rev Oncol Hematol; 1992 Nov; 13(3):241-70. PubMed ID: 1476655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
